Samuel Martin Biography and Net Worth



Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.

What is Samuel Bates Martin's net worth?

The estimated net worth of Samuel Bates Martin is at least $1.02 million as of August 12th, 2022. Mr. Martin owns 24,378 shares of Celldex Therapeutics stock worth more than $1,023,145 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Martin may own. Learn More about Samuel Bates Martin's net worth.

How do I contact Samuel Bates Martin?

The corporate mailing address for Mr. Martin and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Samuel Bates Martin's contact information.

Has Samuel Bates Martin been buying or selling shares of Celldex Therapeutics?

Samuel Bates Martin has not been actively trading shares of Celldex Therapeutics in the last ninety days. Most recently, Samuel Bates Martin sold 17,547 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $36.45, for a transaction totalling $639,588.15. Following the completion of the sale, the chief financial officer now directly owns 24,378 shares of the company's stock, valued at $888,578.10. Learn More on Samuel Bates Martin's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Samuel Bates Martin Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2022Sell17,547$36.45$639,588.1524,378View SEC Filing Icon  
12/23/2021Sell9,500$42.00$399,000.00View SEC Filing Icon  
11/15/2021Sell9,500$43.57$413,915.00View SEC Filing Icon  
8/10/2021Sell2,738$45.25$123,894.50View SEC Filing Icon  
6/9/2020Buy9,750$2.99$29,152.50View SEC Filing Icon  
See Full Table

Samuel Bates Martin Buying and Selling Activity at Celldex Therapeutics

This chart shows Samuel Bates Martin's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $41.97
Low: $41.25
High: $42.19

50 Day Range

MA: $41.20
Low: $35.22
High: $51.88

2 Week Range

Now: $41.97
Low: $22.11
High: $53.18

Volume

579,320 shs

Average Volume

958,280 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52